Rapid Characterization and Selection of SARS-CoV-2 Vaccine Candidates by Bio-Layer Interferometry (BLI) Technology

Sartorius Webinar

Presenter

Wei-Hung Chen, PhD, Research Scientist, Walter Reed Army Institute of Research, The Emerging infectious disease branch

Abstract

SARS-CoV-2 is a zoonotic coronavirus that has caused a global pandemic with more than 10 million confirmed infections across more than 200 countries. The severity of the COVID-19 outbreak highlights the need to develop therapeutic interventions including vaccines, small molecule inhibitors, and immunotherapeutics. Using BLI, we developed a set of assays to identify antibodies with SARS-CoV-2 reactivity, and to enable rapid characterization of SARS-CoV-2 vaccine candidates. Initially, we tested a set of SARS-CoV monoclonal antibodies obtained from BEI resources to assess cross-reactivity to SARS-CoV-2 Spike glycoprotein.

These antibodies target a conserved epitope present on SARS-CoV and related beta-coronaviruses centered on the receptor-binding domain Proline 384. Using this set of re-purposed antibodies and an additional set of potent neutralizing antibodies, we carried out antigenic screening of more than 100 SARS-CoV-2 nanoparticle vaccine candidates. A subset of these immunogens were assessed in mouse immunogenicity studies. Using BLI, we assessed the vaccine-elicited serum response against the SARS-CoV-2 receptor binding domain (RBD) to enable down-selection of vaccine candidates. In addition, using recombinant ACE2 receptor protein, we developed an ACE2 inhibition assay to assess the vaccine-elicited serum ACE2 inhibitory activity. BLI also allows same-day investigation of newly produced protein candidate immunogens, and rapid analysis of animal sera immune responses. 

Request More Information

What other areas are you interested in? (select all that apply)

Please Complete the Form to Watch the Webinar